Estado del arte: Terapias regenerativas en insuficiencia ovárica prematura (IOP). Revisión Sistemática

Camila Ponce Berrú; Pablo Sebastián Basantes Suárez; Fernando Israel Narváez Vásquez; Isabella Ponce Berrú

doi:10.47464/MetroCiencia/vol33/3/2025/13-27

Authors

Camila Ponce Berrú Universidad Internacional del Ecuador https://orcid.org/0009-0003-2057-233X
Pablo Sebastián Basantes Suárez Hospital Metropolitano https://orcid.org/0000-0003-4701-9166
Fernando Israel Narváez Vásquez Hospital Metropolitano https://orcid.org/0000-0001-7165-9257
Isabella Ponce Berrú Universidad de las Américas https://orcid.org/0009-0003-6675-9060

DOI:

https://doi.org/10.47464/MetroCiencia/vol33/3/2025/13-27

Keywords:

premature ovarian insufficiency, mesenchymal stem cells, platelet-rich plasma, regenerative therapy, folliculogenesis, 3D bioprinting

Abstract

Premature ovarian insufficiency (POI) is a condition characterized by the premature loss of ovarian function before the age of 40, affecting fertility and endocrine homeostasis. Conventional therapeutic options, such as hormone replacement therapy (HRT) and oocyte donation, do not restore ovarian function. In this context, regenerative therapies based on mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) have emerged as innovative approaches with the potential to reactivate folliculogenesis and improve ovarian function.

Downloads

Download data is not yet available.

Author Biographies

Camila Ponce Berrú, Universidad Internacional del Ecuador

Posgradista de Ginecología y Obstetricia de la Universidad Internacional del Ecuador; Quito, Ecuador
Pablo Sebastián Basantes Suárez, Hospital Metropolitano

Especialista en Ginecología y Obstetricia, Médico Tratante Hospital Metropolitano; Quito, Ecuador
Fernando Israel Narváez Vásquez, Hospital Metropolitano

Especialista en Medicina Interna, Médico Tratante Hospital Metropolitano; Quito, Ecuador
Isabella Ponce Berrú, Universidad de las Américas

Estudiante de Medicina de la Universidad de las Américas; Quito, Ecuador

References

European Society for Human Reproduction and Embryology Guideline Group on Premature Ovarian Insufficiency, Webber L, Davies M, Anderson R, Bartlett J, Braat D, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.

Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PLoS One. 2014;9(3):e89597.

Bentzen JG, Forman JL, Larsen EC, Pinborg A, Johannsen TH, Schmidt L, et al. Maternal menopause as a predictor of anti-Müllerian hormone level and antral follicle count in daughters during reproductive age. Hum Reprod. 2013;28(1):247–255.

Ossewaarde ME, Bots ML, Verbeek AL, Peeters PH, van der Graaf Y, Grobbee DE, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology. 2005;16(4):556–562.

Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604–606.

Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019;1–9.

Casper RF. Clinical manifestations and diagnosis of menopause. UpToDate. 2011.

Driscoll MA, Davis MC, Aiken LS, Yeung EW, Sterling EW, Vanderhoof V, et al. Psychosocial vulnerability, resilience resources, and coping with infertility: a longitudinal model of adjustment to primary ovarian insufficiency. Ann Behav Med. 2016;50(2):272–284.

Yen SSC. Reproductive Endocrinology. W.B. Saunders, Harcourt Asia; 2001.

De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911–921.

Nelson LM. Clinical practice. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–614.

Wang S, Sun M, Yu L, Wang Y, Yao Y, Wang D. Niacin inhibits apoptosis and rescues premature ovarian failure. Cell Physiol Biochem. 2018;50(6):2060–2070.

Lumsden MA, Davies M, Sarri G, GDG for MDaMNCGN. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) Guideline. JAMA Intern Med. 2016;176(8):1205–1206.

Abd-Allah SH, Shalaby SM, Pasha HF, El-Shal AS, Raafat N, Shabrawy SM, et al. Mechanistic action of mesenchymal stem cell injection in the treatment of chemically induced ovarian failure in rabbits. Cytotherapy. 2013;15:64–75.

Abreu SC, Weiss DJ, Rocco PR. Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? Stem Cell Res Ther. 2016;7:53.

Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, et al. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007;109:693–702.

Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, et al. Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol. 2009;161:179–187.

Bao R, Xu P, Wang Y, Wang J, Xiao L, Li G, et al. Bone marrow-derived mesenchymal stem cells transplantation rescues premature ovarian insufficiency induced by chemotherapy. Gynecol Endocrinol. 2018;34:320–326.

Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev. 2011;10:410–415.

Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, et al. Human bone marrow-derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142–9149.

Binder AK, Rodriguez KF, Hamilton KJ, Stockton PS, Reed CE, Korach KS. The absence of ER-beta results in altered gene expression in ovarian granulosa cells isolated from in vivo preovulatory follicles. Endocrinology. 2013;154:2174–2187.

Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb Vasc Biol. 2013;33:186–192.

Team IS. Variations in reproductive events across life: a pooled analysis of data from 505,147 women across 10 countries. Hum Reprod. 2019;34(5):881–893.

Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199–206.

Takahashi TA, Johnson KM. Menopause. Med Clin North Am. 2015;99(3):521–534.

Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. Obstet Gynecol. 2014;124(1):193–197.

Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16(2):51–56.

Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a meta-analysis. Climacteric. 2016;19(1):27–36.

Archer DF. Premature menopause increases cardiovascular risk. Climacteric. 2009;12(Suppl 1):26–31.

Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65(2):161–166.